Targeted prodrug cytosine deaminase fusion carrier and application thereof
The present invention provides a targeted prodrug enzyme fusion carrier comprising a targeted molecule and a prodrug enzyme. The targeted prodrug enzyme fusion carrier can effectively identify and bind to tumor cells and tumor-induced tumor angiogenesis. The targeted prodrug enzyme fusion carrier also has a targeted prodrug enzyme fusion protein and a theranostic system utilizing the method of in vivo nuclear medicine for the clinical diagnosis and treatment of individual patients with tumors.
1. A targeted prodrug enzyme fusion carrier for identifying and binding a tumor cell or/and an angiogenic endothelial cell of tumor tissues, and diagnosing and treating cancer, comprising a prodrug enzyme at least,
wherein the prodrug enzyme is selected from the group consisting of yeast cytosine deaminase (yCD) (SEQ ID NO: 1), E. coli . cytosine deaminase (EcCD) (SEQ ID NO: 17), and EcCD_D314A (SEQ ID NO: 18),
when the prodrug enzyme is yCD (SEQ ID NO: 1), the targeted prodrug enzyme fusion carrier is consisting of RGD4C-yCD (SEQ ID NO: 3) and RGD4C_yCD_yUPRT (SEQ ID NO: 4),
when the prodrug enzyme is EcCD (SEQ ID NO: 17), the targeted prodrug enzyme fusion carrier is consisting of RGD4C_EcCD_WT (SEQ ID NO: 19),
when the prodrug enzyme is EcCD_D314A (SEQ ID NO: 18), the targeted prodrug enzyme fusion carrier is consisting of RGD4C_EcCD_D314A (SEQ ID NO: 20),
wherein the targeted prodrug enzyme fusion carrier can convert a 5-fluorocytosine (5-FC) into a 5-fluorouracil (5-FU),
wherein the targeted prodrug enzyme fusion carrier is administered a therapeutically effective amount to a subject in need thereof, wherein the subject is diagnosed with cancer.
2. A targeted prodrug enzyme fusion carrier for identifying and binding a tumor cell or/and an angiogenic endothelial cell of tumor tissues, and diagnosing and treating cancer, comprising at least a prodrug enzyme, wherein the prodrug enzyme is selected from the group consisting of yeast cytosine deaminase (yCD) (SEQ ID NO: 1), E. coli . cytosine deaminase (EcCD) (SEQ ID NO: 17), and EcCD_D314A (SEQ ID NO: 18),
when the prodrug enzyme is yCD (SEQ ID NO: 1), the targeted prodrug enzyme fusion carrier is selected from the group consisting of RGD_EGF_yCD (SEQ ID NO: 5), RGD4C_EGF_yCD (SEQ ID NO: 7), yCD_RGD_EGF (SEQ ID NO: 9), yCD_RGD4C_EGF (SEQ ID NO: 11), RGD_VEGF_yCD (SEQ ID NO: 13), RGD4C_VEGF_yCD (SEQ ID NO: 15), RGD_EGF_yCD_yUPRT (SEQ ID NO: 6), RGD4C_EGF_yCD_yUPRT (SEQ ID NO: 8), yCD_yUPRT_RGD_EGF (SEQ ID NO: 10), yCD_yUPRT_RGD4C_EGF (SEQ ID NO: 12), RGD_VEGF_yCD_yUPRT (SEQ ID NO: 14), and RGD4C_VEGF_yCD_yUPRT (SEQ ID NO: 16),
when the prodrug enzyme is EcCD (SEQ ID NO: 17), the targeted prodrug enzyme fusion carrier is further selected from the group consisting of RGD_EGF_EcCD_WT (SEQ ID NO: 21), RGD4C_EGF_EcCD_WT (SEQ ID NO: 23), EcCD_WT_RGD_EGF (SEQ ID NO: 25), EcCD_WT_RGD4C_EGF (SEQ ID NO: 27), RGD_VEGF_EcCD_WT (SEQ ID NO: 29), RGD4C_VEGF_EcCD_WT (SEQ ID NO: 31),
when the prodrug enzyme is EcCD_D314A (SEQ ID NO: 18), the targeted prodrug enzyme fusion carrier is further selected from the group consisting of RGD_EGF_EcCD_D314A (SEQ ID NO: 22), RGD4C_EGF_EcCD_D314A (SEQ ID NO: 24), EcCD_D314A_RGD_EGF (SEQ ID NO: 26), EcCD_D314A_RGD4C_EGF (SEQ ID NO: 28), RGD_VEGF_EcCD_D314A (SEQ ID NO: 30), and RGD4C_VEGF_EcCD_D314A (SEQ ID NO: 32),
wherein the targeted prodrug enzyme fusion carrier can convert a 5-fluorocytosine (5-FC) into a 5-fluorouracil (5-FU),
wherein the targeted prodrug enzyme fusion carrier is administered a therapeutically effective amount to a subject in need thereof, wherein the subject is diagnosed with cancer.
3. The targeted prodrug enzyme fusion carrier according to claim 1 , further comprises a marker molecule.
4. The targeted prodrug enzyme fusion carrier according to claim 3 , wherein the marker molecule is selected from the group consisting of a radionuclide and a fluorescent protein.
5. The targeted prodrug enzyme fusion carrier according to claim 4 , wherein the radionuclide is selected from the indium-111 ( 111 In), gallium-67, gallium-68, yttrium-90 and lutetium-177.
6. The targeted prodrug enzyme fusion carrier according to claim 5 , further comprises a metal chelating agent.
7. The targeted prodrug enzyme fusion carrier according to claim 6 , wherein the metal chelating agent is selected from the group consisting of DTPA, NOTA and DOTA.
8. The targeted prodrug enzyme fusion carrier according to claim 7 , wherein the molar ratio of the prodrug enzyme and the metal chelating agent is less than 20%.
9. A kit comprising the targeted prodrug enzyme fusion carrier of claim 1 and a prodrug, wherein the prodrug is 5 fluorocytosine (5-FC).